A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L

被引:143
作者
Ahlers, JD
Belyakov, IM
Terabe, M
Koka, R
Donaldson, DD
Thomas, EK
Berzofsky, JA [1 ]
机构
[1] NCI, Mol Immunogenet & Vaccine Res Sect, Metab Branch, NIH, Bethesda, MD 20892 USA
[2] Wyeth Genet Inst, Andover, MA 01810 USA
[3] Immunex Res & Dev Corp, Seattle, WA 98101 USA
关键词
D O I
10.1073/pnas.192251199
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Although a role for CD4(+) helper cells in CD8(+) cytotoxic T lymphocyte (CTL) induction by vaccines is widely recognized, much less is known about a counterbalancing role of CD4(+) T cells in down-modulating this response, or about ways to optimize vaccine responses through abrogation of this negative regulatory mechanism. Here, we discovered a synergistic enhancement of vaccine-mediated CTL induction and protection by the relief of suppression through depletion of regulatory CD4(+) cells, including CD4(+) NKT cells, or blockade of IL-13 made by these cells, combined with the cytokine granulocyte/macrophage colony-stimulating factor and the costimulatory molecule CD40L. Indeed, in the absence of helper epitopes, granulocyte/macrophage colony-stimulating factor and the helper-mimetic molecule CD40L are not sufficient to replace help to induce CTL without abrogation of CD4+ T cell-mediated suppression, suggesting a role for T cell help in overcoming suppression. The increased CTL induction translated to striking protection against viral infection by a vaccine by using this synergistic combined approach. These results argue for a push-pull approach to maximize vaccine efficacy, especially for HIV and cancer.
引用
收藏
页码:13020 / 13025
页数:6
相关论文
共 51 条
[1]  
AHLERS JD, 1993, J IMMUNOL, V150, P5647
[2]   Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence [J].
Ahlers, JD ;
Takeshita, T ;
Pendleton, CD ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) :10856-10861
[3]  
Ahlers JD, 1997, J IMMUNOL, V158, P3947
[4]   Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization [J].
Ahlers, JD ;
Dunlop, N ;
Pendleton, CD ;
Newman, M ;
Nara, PL ;
Berzofsky, JA .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (04) :259-272
[5]   High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection [J].
Ahlers, JD ;
Belyakov, IM ;
Thomas, EK ;
Berzofsky, JA .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (11) :1677-1685
[6]   Mechanisms of cytokine synergy essential for vaccine protection against viral challenge [J].
Ahlers, JD ;
Belyakov, IM ;
Matsui, S ;
Berzofsky, JA .
INTERNATIONAL IMMUNOLOGY, 2001, 13 (07) :897-908
[7]   Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL [J].
Belyakov, IM ;
Ahlers, JD ;
Clements, JD ;
Strober, W ;
Berzofsky, JA .
JOURNAL OF IMMUNOLOGY, 2000, 165 (11) :6454-6462
[8]   Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques [J].
Belyakov, IM ;
Hel, Z ;
Kelsall, B ;
Kuznetsov, VA ;
Ahlers, JD ;
Nacsa, J ;
Watkins, DI ;
Allen, TM ;
Sette, A ;
Altman, J ;
Woodward, R ;
Markham, PD ;
Clements, JD ;
Franchini, G ;
Strober, W ;
Berzofsky, JA .
NATURE MEDICINE, 2001, 7 (12) :1320-1326
[9]   Help for cytotoxic-T-cell responses is mediated by CD40 signalling [J].
Bennett, SRM ;
Carbone, FR ;
Karamalis, F ;
Flavell, RA ;
Miller, JFAP ;
Heath, WR .
NATURE, 1998, 393 (6684) :478-480
[10]   Strategies for designing and optimizing new generation vaccines [J].
Berzofsky, JA ;
Ahlers, JD ;
Belyakov, IM .
NATURE REVIEWS IMMUNOLOGY, 2001, 1 (03) :209-219